# Orthocell Achieves Strongest Month of U.S. Remplir™ Sales Since Launch

- Link: https://www.thailand-business-news.com/pr-news/orthocell-achieves-strongest-month-of-u-s-remplir-sales-since-launch
- Published: 2026-11-02T07:08:00+07:00
- Author: PR Newswire

◦ **Remplir™ is a collagen nerve wrap designed to support the repair and protection
   of peripheral nerves. Designed and manufactured by **[**Orthocell Ltd**](https://orthocell.com/au/home/)**
   in Australia, the FDA-cleared device is emerging as a category leader in key 
   international markets.**
 ◦ **Sales of 92 Remplir™ units in October 2026 generated AU$279,000 in revenue,
   representing an 84% uplift on average monthly sales of 50 units during Q1 FY27.**
 ◦ **The groundwork laid to launch Remplir in the U.S. is now translating into tangible
   revenue as Orthocell’s commercial strategy gains traction.**
 ◦ **The result reflects growing surgeon adoption, increasing repeat use, a broader
   base of actively selling distributor representatives and expanded hospital access
   across key U.S. markets.**
 ◦ **October’s performance provides encouraging evidence of strengthening U.S. commercial
   momentum and supports the outlook for continued Remplir revenue growth.**

PERTH, Australia, Nov. 2, 2026 /PRNewswire/ — Orthocell Limited (ASX: OCC) is pleased
to provide an update on U.S. commercial performance for its nerve repair product,
Remplir™, following the completion of October 2026 trading. The update is being 
provided ahead of the Company’s Annual General Meeting on 6 November 2026, with 
standard quarterly reporting to continue thereafter.

Orthocell achieved **U.S. sales of 92 Remplir units in October, generating AU$279,000
in revenue and representing an 84% uplift on the average monthly sales of 50 units
during Q1 FY27.**

This represents the strongest month of U.S. sales since launch and reflects growing
surgeon adoption, increasing repeat utilisation, an expanding network of actively
selling distributor representatives and broader hospital access across key U.S. 
markets. These results demonstrate progress in converting expanded market access
into increased product utilisation and revenue.

**Orthocell CEO and MD, Paul Anderson, said:** "October represents an important 
milestone in Orthocell’s U.S. commercialisation, with the groundwork laid over the
past 12 months now translating into tangible revenue.

"The improvement in key commercial indicators demonstrates that Remplir is gaining
traction in the U.S. market. While establishing a new medical technology in a large
market takes time and sustained effort, our focus remains on accelerating surgeon
adoption, expanding hospital access and increasing product utilisation."

**Commercial Growth Accelerating**

Orthocell has consistently communicated that commercialisation of innovative medical
technologies follows a progressive adoption pathway as surgeons gain familiarity
with new treatment options and hospital access expands through Value Assessment 
Committee (VAC) approvals.

October’s performance represents a significant uplift in U.S. sales, reflecting 
progress in converting expanding market access into commercial utilisation. This
U.S. progress, combined with regulatory approvals across seven international jurisdictions
and established manufacturing capability, provides a foundation for continued commercial
growth.

Orthocell will continue to focus on expanding surgeon adoption, strengthening its
active distributor network and growing Remplir utilisation across approved markets
to support sustainable revenue growth.

**Orthocell Chairman, John Van Der Wielen, commented**: "The Board is encouraged
by the October sales result and the progress achieved in U.S. commercialisation.
Orthocell has invested in the commercial infrastructure required to support Remplir’s
expansion and is continuing to expand its manufacturing capacity in anticipation
of increased demand.

"The Board remains confident in the product’s significant U.S. market potential 
and the Company’s strategy to translate growing market adoption into long-term commercial
success."

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Orthocell Achieves Strongest Month of U.S. Remplir™ Sales Since Launch ](http://www.prnasia.com/story/archive/5086377_AE86377_0?rand=184833)